Graeme Martin Currie - 01 Mar 2024 Form 4/A Insider Report for Pasithea Therapeutics Corp. (KTTA)

Reporting relationship: Chief Development Officer
Issuer ticker: KTTA
Reported as of: 01 Mar 2024
Net transaction value: $0
SEC form: 4/A
Accepted by SEC: 05 Apr 2024, 21:45:13 UTC
Original report date: 01 Mar 2024
Prior SEC filing: 03 Jul 2023
Source filing: View source filing
Reporting owner signature: /s/ Graeme Currie

Key filing fact

Graeme Martin Currie filed Form 4/A for Pasithea Therapeutics Corp. (KTTA) on 05 Apr 2024.

Key facts

This page summarizes Graeme Martin Currie's Form 4/A filing for Pasithea Therapeutics Corp. (KTTA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Apr 2024, 21:45.

Change

Previous filing in this sequence was filed on 03 Jul 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KTTA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +5,938
Change %
Price: $0.000000
Shares after: 5,938
Date: 01 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,938
Exercise price: $8.13
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share.

Footnote F2

The option award (the "Option") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The Option fully vested upon issuance and became exercisable on March 1, 2024.

SEC remarks

On January 2, 2024, the Issuer effected a reverse stock split of its Common Stock at a ratio of 1-for-20 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the shares of Common Stock, and the exercise price and shares of Common Stock underlying outstanding equity awards, have been adjusted accordingly versus any amounts previously reported by the Reporting Person.